Abstract
Important advances have been made within in past few years in the treatment of glioma, however, the longterm prognosis after resection of glioma remains unsatisfactory as a result of a high incidence of recurrence. To solve this problem, many biologic therapies have been investigated. In the present study, we report a nanoparticle with properties for dual targeting of tumor cells and the neovasculature. The nanoparticle comprises encoding vasohibin and RGD 12-mer cationic peptide RKKRRQRRRRGD (Tat49-57RGD) peptides, which a nuclear nanoparticle within an extranuclear peptide envelope. Our results demonstrate that the nanoparticle could prevent tumor angiogenesis and inhibit tumor growth via attenuating neovasculature formation and inducing tumor apoptosis. Therefore, the dual targeting strategy of tumor cells and neovasculature represents an integrative approach in glioma therapy. This can be extended to additional agents to target multiple signal pathways or distinct tumor compartments.
Keywords: Dual targeting, U251 cells, vasohibin, RGD peptides, glioma, long-term prognosis , cationic peptide , tumor compartments, Traditional biologic , tumor vasculatures , therapeutical strategy , vasohibin plasmid , vasohibin , fetal bovine serum
Current Neurovascular Research
Title:Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth
Volume: 9 Issue: 2
Author(s): Hongjie Chen, Kaichun Fan, Shousen Wang, Zheng Liu and Zhaocong Zheng
Affiliation:
Keywords: Dual targeting, U251 cells, vasohibin, RGD peptides, glioma, long-term prognosis , cationic peptide , tumor compartments, Traditional biologic , tumor vasculatures , therapeutical strategy , vasohibin plasmid , vasohibin , fetal bovine serum
Abstract: Important advances have been made within in past few years in the treatment of glioma, however, the longterm prognosis after resection of glioma remains unsatisfactory as a result of a high incidence of recurrence. To solve this problem, many biologic therapies have been investigated. In the present study, we report a nanoparticle with properties for dual targeting of tumor cells and the neovasculature. The nanoparticle comprises encoding vasohibin and RGD 12-mer cationic peptide RKKRRQRRRRGD (Tat49-57RGD) peptides, which a nuclear nanoparticle within an extranuclear peptide envelope. Our results demonstrate that the nanoparticle could prevent tumor angiogenesis and inhibit tumor growth via attenuating neovasculature formation and inducing tumor apoptosis. Therefore, the dual targeting strategy of tumor cells and neovasculature represents an integrative approach in glioma therapy. This can be extended to additional agents to target multiple signal pathways or distinct tumor compartments.
Export Options
About this article
Cite this article as:
Chen Hongjie, Fan Kaichun, Wang Shousen, Liu Zheng and Zheng Zhaocong, Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth, Current Neurovascular Research 2012; 9 (2) . https://dx.doi.org/10.2174/156720212800410902
DOI https://dx.doi.org/10.2174/156720212800410902 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Elaborating the Role of Natural Products on the Regulation of Autophagy and their Potentials in Breast Cancer Therapy
Current Cancer Drug Targets Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Double-Faced Role of Human Mesenchymal Stem Cells and their Role/Challenges in Cancer Therapy
Current Stem Cell Research & Therapy Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Anti-Cancer Agents in Medicinal Chemistry Novel Oncogenic Protein Kinase Inhibitors for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Endomorphin Derivatives with Improved Pharmacological Properties
Current Medicinal Chemistry Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry Glioblastoma Tumor Initiating Cells: Therapeutic Strategies Targeting Apoptosis and MicroRNA Pathways
Current Molecular Medicine Small Heat Shock Proteins (sHSPs) As Potential Drug Targets
Current Pharmaceutical Biotechnology Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Dual Induction of Mitochondrial Apoptosis and Senescence in Chronic Myelogenous Leukemia by Myrtucommulone A
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells
Anti-Cancer Agents in Medicinal Chemistry Graphene Family of Nanomaterials: Reviewing Advanced Applications in Drug delivery and Medicine
Current Drug Delivery Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology Trends in Malignant Glioma Monoclonal Antibody Therapy
Current Cancer Therapy Reviews